Navigation

hepatitis a/b vaccine (Twinrix)

 

Classes: Vaccines, Inactivated, Viral; Vaccines, Travel

Dosing and uses of Twinrix (hepatitis a/b vaccine)

 

Adult dosage forms and strengths

hepatitis A/hepatitis B viruses

IM suspension

  • (720 ELISA units/20mcg)/1mL

 

Hepatitis A & B Immunization

Standard dosing: 1 mL IM at 0, 1, and 6 months

Accelerated dosing: 1 mL IM on days 0, 7, and 21-30, followed by a 4th dose at 12 months

 

Other Information

Up-to-date vaccination schedules available at https://www.cdc.gov/vaccines/schedules/hcp/index.htmL

See Also

  • Hepatitis A Vaccine
  • Hepatitis B Vaccine

 

Pediatric dosage forms and strengths

<18 years: Safety and efficacy not established

 

Twinrix (hepatitis a/b vaccine) adverse (side) effects

Suspected adverse events after administration of any vaccine may be reported to Vaccine Adverse Events Reporting System (VAERS), 1-800-822-7967

 

>10%

Soreness (37%)

Headache (22%)

Fatigue (14%)

 

1-10%

Redness (8%)

Diarrhea (5%)

Nausea (4%)

Fever (4%)

Swelling (4%)

 

Warnings

Contraindications

Hypersensitivity to yeast

 

Cautions

Contains thimerosal (<1 mcg mercury)

 

Pregnancy and lactation

Pregnancy category: C

Lactation: not known if excreted in breast milk

 

Pregnancy categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

 

Pharmacology of Twinrix (hepatitis a/b vaccine)

Mechanism of action

Inactivated HAV combined with purified HBsAg induce Ab production

Onset: unknown

Duration: unknown

These products convey active immunity via stimulation of production of endogenously produced antibodies

The onset of protection from disease is relatively slow, but duration is long lasting (years)